These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28715644)

  • 1. Detection and identification of serum protein peak at 6648 m/z as a novel indicator in breast cancer based on mass spectrometry.
    Song D; Yue L; Zhan Y; Zhang J; Yan Z; Fan Y; Yang H; Zhang D; Liu Q; Xia Z; Qin P; Jia J; Yue M; Yu J; Zheng S; Yang F; Wang J
    Discov Med; 2017 May; 23(128):283-294. PubMed ID: 28715644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer.
    Chung L; Moore K; Phillips L; Boyle FM; Marsh DJ; Baxter RC
    Breast Cancer Res; 2014 Jun; 16(3):R63. PubMed ID: 24935269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel serum peptides biomarkers for female breast cancer patients in Western China.
    Yang J; Xiong X; Liu S; Zhu J; Luo M; Liu L; Zhao L; Qin Y; Song T; Huang C
    Proteomics; 2016 Mar; 16(6):925-34. PubMed ID: 26705257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and prognostic role of serum protein peak at 6449 m/z in gastric adenocarcinoma based on mass spectrometry.
    Song D; Yue L; Li H; Zhang J; Yan Z; Fan Y; Yang H; Liu Q; Zhang D; Xia Z; Qin P; Jia J; Yue M; Yu J; Zheng S; Yang F; Wang J
    Br J Cancer; 2016 Apr; 114(8):929-38. PubMed ID: 27002935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer.
    Pietrowska M; Marczak L; Polanska J; Behrendt K; Nowicka E; Walaszczyk A; Chmura A; Deja R; Stobiecki M; Polanski A; Tarnawski R; Widlak P
    J Transl Med; 2009 Jul; 7():60. PubMed ID: 19594898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and prognostic significance of serum apolipoprotein C-I in triple-negative breast cancer based on mass spectrometry.
    Song D; Yue L; Zhang J; Ma S; Zhao W; Guo F; Fan Y; Yang H; Liu Q; Zhang D; Xia Z; Qin P; Jia J; Yue M; Yu J; Zheng S; Yang F; Wang J
    Cancer Biol Ther; 2016 Jun; 17(6):635-47. PubMed ID: 27260686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum biomarker 3144 m/z for prognostic detection in Chinese postmenopausal breast cancer patients.
    Gao Y; Xu S; Cao W; Chen Z; Wang X; Zou D
    J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C68-73. PubMed ID: 26323928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum immunoglobulin G Fc region N-glycosylation profiling by matrix-assisted laser desorption/ionization mass spectrometry can distinguish breast cancer patients from cancer-free controls.
    Kawaguchi-Sakita N; Kaneshiro-Nakagawa K; Kawashima M; Sugimoto M; Tokiwa M; Suzuki E; Kajihara S; Fujita Y; Iwamoto S; Tanaka K; Toi M
    Biochem Biophys Res Commun; 2016 Jan; 469(4):1140-5. PubMed ID: 26740182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Apolipoprotein C-I Peptides as a Potential Biomarker and its Biological Roles in Breast Cancer.
    Sun Y; Zhang J; Guo F; Zhao W; Zhan Y; Liu C; Fan Y; Wang J
    Med Sci Monit; 2016 Apr; 22():1152-60. PubMed ID: 27052600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery.
    Boccardo F; Rubagotti A; Nuzzo PV; Argellati F; Savarino G; Romano P; Damonte G; Rocco M; Profumo A
    Int J Cancer; 2015 Nov; 137(10):2394-402. PubMed ID: 25994113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection and identification of potential biomarkers of breast cancer.
    Fan Y; Wang J; Yang Y; Liu Q; Fan Y; Yu J; Zheng S; Li M; Wang J
    J Cancer Res Clin Oncol; 2010 Aug; 136(8):1243-54. PubMed ID: 20237941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of serum protein markers for breast cancer relapse with SELDI-TOF MS.
    Lei L; Wang XJ; Zheng ZG; Huang J; Cao WM; Chen ZH; Shao XY; Cai JF; Ye WW; Lu HY
    Anat Rec (Hoboken); 2011 Jun; 294(6):941-4. PubMed ID: 21548109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
    Fiedler GM; Leichtle AB; Kase J; Baumann S; Ceglarek U; Felix K; Conrad T; Witzigmann H; Weimann A; Schütte C; Hauss J; Büchler M; Thiery J
    Clin Cancer Res; 2009 Jun; 15(11):3812-9. PubMed ID: 19470732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new tumor biomarker, serum protein peak at 3,144 m/z, in patients with node-positive breast cancer.
    Chen Z; Xu S; Su D; Liu W; Yang H; Xie S; Meng X; Lei L; Wang X
    Clin Transl Oncol; 2015 Jun; 17(6):486-94. PubMed ID: 25511546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-Based Proteomic Assay to Identify Breast Cancer.
    Henderson MC; Hollingsworth AB; Gordon K; Silver M; Mulpuri R; Letsios E; Reese DE
    PLoS One; 2016; 11(8):e0157692. PubMed ID: 27508384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
    Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
    Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reproducibility of serum protein profiling by systematic assessment using solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry.
    Callesen AK; Christensen Rd; Madsen JS; Vach W; Zapico E; Cold S; Jørgensen PE; Mogensen O; Kruse TA; Jensen ON
    Rapid Commun Mass Spectrom; 2008; 22(3):291-300. PubMed ID: 18181248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of serological proteomic methods to find biomarkers associated with breast cancer.
    Rui Z; Jian-Guo J; Yuan-Peng T; Hai P; Bing-Gen R
    Proteomics; 2003 Apr; 3(4):433-9. PubMed ID: 12687611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic Screening for Serum Biomarkers for Cervical Cancer and Their Clinical Significance.
    Chen Y; Xiong X; Wang Y; Zhao J; Shi H; Zhang H; Wang Y; Wei Y; Xue W; Zhang J
    Med Sci Monit; 2019 Jan; 25():288-297. PubMed ID: 30625128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of blood-based biomarkers for the early detection of breast cancer.
    Loke SY; Lee ASG
    Eur J Cancer; 2018 Mar; 92():54-68. PubMed ID: 29413690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.